Waters 과거 수익 실적
과거 기준 확인 2/6
Waters은 연평균 3.3%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 11.7%였습니다. 매출은 연평균 5.5%의 비율로 증가했습니다. Waters의 자기자본이익률은 38.8%이고 순이익률은 21.4%입니다.
주요 정보
3.3%
수익 성장률
5.8%
EPS 성장률
| Life Sciences 산업 성장 | 21.5% |
| 매출 성장률 | 5.5% |
| 자기자본 수익률 | 38.8% |
| 순이익 | 21.4% |
| 최근 수익 업데이트 | 28 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Is Waters (NYSE:WAT) A Risky Investment?
Nov 21
Waters Corp: Short Reinvestment Runway Diminishes High Multiples
Nov 13Waters Corporation's (NYSE:WAT) Price Is Out Of Tune With Earnings
Sep 11A Look At The Fair Value Of Waters Corporation (NYSE:WAT)
Aug 24Waters Corp.: Embedded Expectations High Under Present Conditions
Aug 15Does Waters (NYSE:WAT) Have A Healthy Balance Sheet?
Aug 06Should You Think About Buying Waters Corporation (NYSE:WAT) Now?
Jul 19Waters Corporation's (NYSE:WAT) Business Is Yet to Catch Up With Its Share Price
May 26Waters Corporation: Still Struggling A Bit
May 24Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)
Apr 25Is It Too Late To Consider Buying Waters Corporation (NYSE:WAT)?
Apr 07We Think Waters (NYSE:WAT) Can Stay On Top Of Its Debt
Mar 19Waters Corporation: A Great (Share Price) Run
Mar 11Waters Corporation (NYSE:WAT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$323
Feb 09Waters Corporation's (NYSE:WAT) Price Is Out Of Tune With Earnings
Jan 09Waters Corporation: High Quality Niche Company In Mass Spectrometry
Dec 28A Look At The Fair Value Of Waters Corporation (NYSE:WAT)
Dec 10Is There Now An Opportunity In Waters Corporation (NYSE:WAT)?
Nov 25Waters Corporation: Appealing Levels Are Offset By Weaker Performance
Nov 13Waters (NYSE:WAT) Seems To Use Debt Quite Sensibly
Oct 26Waters Corporation: Buybacks Ceased, Incremental Returns Languishing (Rating Downgrade)
Sep 27What Does Waters Corporation's (NYSE:WAT) Share Price Indicate?
Aug 21Calculating The Intrinsic Value Of Waters Corporation (NYSE:WAT)
Aug 03Waters Corporation: Temporary Headwinds Present A Buying Opportunity
Jul 18These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well
Jul 16Is Now The Time To Look At Buying Waters Corporation (NYSE:WAT)?
May 23A Look At The Intrinsic Value Of Waters Corporation (NYSE:WAT)
Apr 29Here's Why Waters (NYSE:WAT) Can Manage Its Debt Responsibly
Apr 08What Is Waters Corporation's (NYSE:WAT) Share Price Doing?
Feb 22Waters Q4 2022 Earnings Preview
Feb 14Waters Corp.: Now Best Price-Positioned Medical Services Stock
Feb 02Waters Corporation (NYSE:WAT) Shares Could Be 31% Above Their Intrinsic Value Estimate
Jan 26Does Waters (NYSE:WAT) Have A Healthy Balance Sheet?
Jan 05Should You Think About Buying Waters Corporation (NYSE:WAT) Now?
Nov 24Waters Corporation: Tactical Buy Seeking Upside Objectives Of $345, $363
Nov 16Waters Q3 2022 Earnings Preview
Oct 31Estimating The Fair Value Of Waters Corporation (NYSE:WAT)
Oct 19Waters announces €6M R&D investment at Wexford facility
Oct 07Is Waters (NYSE:WAT) Using Too Much Debt?
Oct 01Do Waters' (NYSE:WAT) Earnings Warrant Your Attention?
Aug 23Waters Corporation: Thesis Unchanged
Aug 18Is There Now An Opportunity In Waters Corporation (NYSE:WAT)?
Aug 05수익 및 비용 분석
수익 및 비용 분석
Waters 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 28 Sep 24 | 2,905 | 623 | 690 | 180 |
| 29 Jun 24 | 2,877 | 596 | 688 | 177 |
| 30 Mar 24 | 2,909 | 604 | 690 | 177 |
| 31 Dec 23 | 2,956 | 642 | 697 | 175 |
| 30 Sep 23 | 2,995 | 653 | 690 | 179 |
| 01 Jul 23 | 2,992 | 675 | 696 | 180 |
| 01 Apr 23 | 2,966 | 689 | 682 | 178 |
| 31 Dec 22 | 2,972 | 708 | 658 | 176 |
| 01 Oct 22 | 2,950 | 697 | 658 | 171 |
| 02 Jul 22 | 2,901 | 702 | 645 | 170 |
| 02 Apr 22 | 2,868 | 705 | 641 | 171 |
| 31 Dec 21 | 2,786 | 693 | 627 | 168 |
| 02 Oct 21 | 2,736 | 695 | 606 | 165 |
| 03 Jul 21 | 2,671 | 660 | 563 | 158 |
| 03 Apr 21 | 2,509 | 616 | 541 | 144 |
| 31 Dec 20 | 2,365 | 522 | 555 | 141 |
| 26 Sep 20 | 2,295 | 504 | 507 | 138 |
| 27 Jun 20 | 2,278 | 515 | 524 | 138 |
| 28 Mar 20 | 2,358 | 537 | 522 | 143 |
| 31 Dec 19 | 2,407 | 592 | 526 | 143 |
| 28 Sep 19 | 2,405 | 577 | 582 | 144 |
| 29 Jun 19 | 2,406 | 580 | 584 | 145 |
| 30 Mar 19 | 2,403 | 591 | 589 | 144 |
| 31 Dec 18 | 2,420 | 594 | 585 | 143 |
| 29 Sep 18 | 2,392 | 55 | 543 | 140 |
| 30 Jun 18 | 2,380 | 51 | 550 | 139 |
| 31 Mar 18 | 2,342 | 27 | 540 | 136 |
| 31 Dec 17 | 2,309 | 20 | 545 | 133 |
| 30 Sep 17 | 2,251 | 548 | 512 | 130 |
| 01 Jul 17 | 2,212 | 537 | 501 | 127 |
| 01 Apr 17 | 2,190 | 533 | 502 | 127 |
| 31 Dec 16 | 2,167 | 522 | 512 | 125 |
| 01 Oct 16 | 2,125 | 498 | 508 | 121 |
| 02 Jul 16 | 2,099 | 490 | 509 | 121 |
| 02 Apr 16 | 2,057 | 467 | 502 | 119 |
| 31 Dec 15 | 2,042 | 469 | 493 | 119 |
| 03 Oct 15 | 2,040 | 469 | 498 | 119 |
| 04 Jul 15 | 2,032 | 467 | 496 | 116 |
| 04 Apr 15 | 2,019 | 457 | 501 | 112 |
| 31 Dec 14 | 1,989 | 432 | 502 | 108 |
| 27 Sep 14 | 1,971 | 422 | 501 | 106 |
| 28 Jun 14 | 1,935 | 406 | 500 | 102 |
| 29 Mar 14 | 1,904 | 399 | 495 | 100 |
| 31 Dec 13 | 1,904 | 450 | 493 | 101 |
양질의 수익: WAT 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: WAT 의 현재 순이익 이익률 (21.4%) 작년보다 낮습니다 (21.8%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: WAT 의 수입은 지난 5년 동안 매년 3.3% 씩 증가했습니다.
성장 가속화: WAT 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.
수익 대 산업: WAT 은 지난 1년 동안 마이너스 수익 성장( -4.7% )을 기록하여 Life Sciences 업계 평균( -4.7% ).
자기자본 수익률
높은 ROE: WAT 의 자본 수익률( 38.84% )이 높음이지만, 이 지표는 높은 부채 수준으로 인해 왜곡됩니다.